Thursday, April 09, 2020 7:32:17 AM
On March 25th, Akers Biosciences (NasdaqCM: AKER) announced a licensing agreement with Premas Biotech to find an effective vaccine for COVID-19. Premas Biotech has over 125 employees and has delivered over 650 proteins and has completed over 240 separate projects for pharmaceutical companies. The company also has four candidates currently in clinical trials globally, and most notable, an oral insulin drug candidate which recently completed a Phase 2b trial in the U.S.
The transcript from that announcement call explains exactly why Akers and Premas believe that the Akers Biosciences/Premas Biotech partnership has the potential to quickly and cost-effectively bring a yeast-based protein COVID-19 vaccine to market.
https://www.khits.com/story/41978191/akers-biosciences-heres-why-the-licensing-deal-with-premas-biotech-could-be-a-game-changer-in-the-race-for-a-covid-19-vaccine
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM